UNCY - Unicycive Therapeutics, Inc.
After hours:
Chart Events
Fast Stochastic
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.5400 |
| Open | 1.5600 |
| Bid | 1.7500 x 1000 |
| Ask | 1.7500 x 1800 |
| Day's Range | 1.5100 - 1.7700 |
| 52 Week Range | 0.4000 - 2.8700 |
| Volume | |
| Avg. Volume | 1,813,793 |
| Market Cap | 26.659M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.40 |
Fair Value
Related Research
ACCESSWIREUnicycive Therapeutics, Inc. and Alarum Technologies Ltd. Interviews to Air on Bloomberg TV on the RedChip Money Report®
RedChip Companies will air new interviews with Unicycive Therapeutics, Inc. (Nasdaq:UNCY) and Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) on The RedChip Money Report® on Bloomberg TV, this Saturday, June 10, at 7 p.m. Eastern Time (ET).
Simply Wall St.Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) Profit Outlook
Unicycive Therapeutics, Inc. ( NASDAQ:UNCY ) is possibly approaching a major achievement in its business, so we would...
GlobeNewswireUnicycive Announces First Quarter 2023 Financial Results and Provides Business Update
Closed on previously announced transformational fundraising that included $30 million financing upfront with up to an additional $100 million tied to the satisfaction of milestones Continued progress with plan to file New Drug Application with the U.S. Food and Drug Administration in Q3 2023, with the potential for approval and launch in 2024 LOS ALTOS, Calif., May 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnol
- GlobeNewswire
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
Data highlights the potential safety and reno-protective effect of UNI-494LOS ALTOS, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced that two datasets highlighting the safety and suggestive efficacy of UNI-494 in animal models were accepted for oral presentation at the upcoming 60th European Renal Association Congress (ERA 2023) taking place f
- GlobeNewswire
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
Closed transformational fundraise that included $30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Financing by new and existing institutional investors from high-profile healthcare-focused funds to support launch and commercialization of investigational new drug, Renazorb™ Company on track to file New Drug Application with the U.S. Food and Drug Administration in mid-2023 with potential for approval and launch in 2024 LOS ALTOS, Calif., March
- Simply Wall St.
Shareholders have faith in Unicycive Therapeutics (NASDAQ:UNCY) as stock climbs 36% in past week, taking one-year gain to 99%
Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right individual stocks, you could make more than that...
News DirectThe Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
By Julian Richard, Benzinga
- GlobeNewswire
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
$30 million financing upfront with up to an additional $100 million tied to satisfaction of milestones Led by Vivo Capital with participation from RA Capital, BVF Partners, Logos Capital, and supported by existing investors Nantahala Capital Partners and Rosalind Advisors Inc. Vivo Capital’s Gaurav Aggarwal, MD to join the Board Company to implement mandatory dividend policy upon achievement of profitability LOS ALTOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasd
News DirectThe Silent Killer: The Impact Of Kidney Disease On Patients And Their Caregivers
By Julian Richard, Benzinga
GlobeNewswireUnicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
Data from two abstracts supporting UNI-494’s potential to treat acute and chronic kidney injury accepted for presentation at the 28th International Conference on Critical Care in Nephrology: the Acute Kidney Injury & CRRT 2023 Conference Highlights key role mitochondria play in disease progression in both acute and chronic kidney injury at 5th Annual Chronic Kidney Disease Drug Development Summit LOS ALTOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a
News DirectUnicycive: The Company Developing Key Kidney Therapies
by Johnny Rice, Benzinga Contributor
News DirectUnicycive: This Biotech Company Receives Promising Results From New Trial
By Johnny Rice, Benzinga
- GlobeNewswire
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
Develops Renazorb opportunity in new market for patients with hyperphosphatemia Agreement includes upfront payment, royalties, and milestone payments LOS ALTOS, Calif., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that it has entered into an exclusive license agreement with Lotus Pharmaceutical (“Lotus”, Taiwan TWSE ticker: 1795) , a leading global pharm
- GlobeNewswire
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
Data support UNI-494’s potential to treat acute kidney disease and underscore the phosphate binding benefits of Renazorb as a potential treatment for hyperphosphatemiaLOS ALTOS, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that three abstracts have been accepted for presentation at the National Kidney Foundation’s (NFK) upcoming Spring Clinical M
- GlobeNewswire
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
Growing body of clinical evidence support the potential of Renazorb and UNI-494 to effectively treat hyperphosphatemia and acute kidney disease, respectivelyLOS ALTOS, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that four abstracts have been accepted for presentation at the upcoming International Society of Nephrology’s World Congress of Nephrol
- GlobeNewswire
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
LOS ALTOS, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the termination of its “at-the-market” equity offering program (the “ATM Offering”) with JonesTrading Institutional Services, LLC as sales agent. The Company elected to terminate the ATM Offering to limit uncertainty and unfavorable dilution for its shareholders. The Company has initiated th
BenzingaUnicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
Unicycive Therapeutics Inc's (NASDAQ: UNCY) pivotal bioequivalence (BE) study comparing Renazorb to Fosrenol has met the primary endpoint. Renazorb is an investigational phosphate binding agent utilizing proprietary nanoparticle technology under development for hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. It potentially provides benefits over currently available treatment options as it requires fewer pills per dose and is swallowed instead of chewed. Also read: Unicyci
- GlobeNewswire
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
Renazorb demonstrates pharmacodynamic bioequivalence to Fosrenol Renazorb’s enhanced product profile features reduced pill burden and small, swallowable tablets, which may improve patient compliance On track to file New Drug Application mid-2023 LOS ALTOS, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the primary endpoint was met in the Compa
- GlobeNewswire
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023LOS ALTOS, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, announced today that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) has completed review of the Clinical Trial Application (CTA) and has issued a notice of acceptance for UNI
- ACCESSWIRE
Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
RedChip Companies will air a new interview with Unicycive Therapeutics, Inc. (NASDAQ:UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 10, at 7 p.m. Eastern Time (ET).
- GlobeNewswire
Unicycive to Participate in Upcoming Investor Conferences
Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial DysfunctionLOS ALTOS, Calif., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced senior management will participate in two upcoming conferences: Sequire Technology ConferenceFormat: Company PresentationDate: Wednesday, November 30, 2022Time: 11:3
BenzingaUnicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
Unicycive Therapeutics Inc (NASDAQ: UNCY) announced key findings of UNI-494 efficacy from a preclinical study in Geographic Atrophy (GA). UNI-494 is a mitochondrial potassium channel (mitochondrial KATP) activator in development for treating diseases affected by mitochondrial dysfunction, such as kidney, liver, and ocular diseases. Mitochondrial dysfunction is implicated in Age-related Macular Degeneration (AMD) progression. GA is an advanced form of AMD. The company evaluated the effect of UNI-
- GlobeNewswire
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
Treatment with UNI-494 improved contrast vision in animal models of geographic atrophy (GA) GA is an advanced form of Age-related Macular Degeneration (AMD) and there are currently no FDA-approved drugs to slow the progression of AMD LOS ALTOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with unmet medical needs, today announced key findings of UNI-494 efficacy from a preclinical s
- GlobeNewswire
Unicycive Announces Third Quarter Financial Results and Provides Business Update
Topline results by year-end as enrollment completed for pivotal bioequivalence study of RENAZORB™ (lanthanum dioxycarbonate), an investigational phosphate binder for the treatment of hyperphosphatemia in Chronic Kidney Disease (CKD) patients on dialysis On track to file New Drug Application for RENAZORB in 2023 Expect clearance for a Phase 1 healthy volunteer study of UNI-494, a novel proprietary drug targeting the SUR2B subunit of the mitochondrial KATP channel, in the UK by year-end LOS ALTOS,
- GlobeNewswire
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
Topline Data Expected by Year End 2022 On Track to File the NDA in 2023 LOS ALTOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has completed the enrollment of subjects in the RENAZORB bioequivalence (BE) study. RENAZORB (lanthanum dioxycarbonate) is an investigational phosphate binding agent utilizing proprietary nanoparticle technology